Medy Tox Valuation
| 086900 Stock | KRW 133,200 400.00 0.30% |
At this time, the firm appears to be overvalued. Medy Tox secures a last-minute Real Value of W111888.0 per share. The latest price of the firm is W133200.0. Our model forecasts the value of Medy Tox from analyzing the firm fundamentals such as Return On Equity of 0.053, profit margin of 0.13 %, and Current Valuation of 989.66 B as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Medy Tox's price fluctuation is very steady at this time. Calculation of the real value of Medy Tox is based on 3 months time horizon. Increasing Medy Tox's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Medy Tox is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Medy Stock. However, Medy Tox's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 133200.0 | Real 111888.0 | Hype 133200.0 |
The real value of Medy Stock, also known as its intrinsic value, is the underlying worth of Medy Tox Company, which is reflected in its stock price. It is based on Medy Tox's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Medy Tox's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Medy Tox helps investors to forecast how Medy stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Medy Tox more accurately as focusing exclusively on Medy Tox's fundamentals will not take into account other important factors: Medy Tox Total Value Analysis
Medy Tox is presently forecasted to have takeover price of 989.66 B with market capitalization of 1 T, debt of 55.38 B, and cash on hands of 71.77 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Medy Tox fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
989.66 B | 1 T | 55.38 B | 71.77 B |
Medy Tox Investor Information
About 27.0% of the company shares are owned by insiders or employees . The company recorded earning per share (EPS) of 1813.31. Medy Tox had not issued any dividends in recent years. The entity had 21:20 split on the 28th of December 2022. Based on the key measurements obtained from Medy Tox's financial statements, Medy Tox is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Medy Tox Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Medy Tox has an asset utilization ratio of 32.0 percent. This suggests that the Company is making W0.32 for each dollar of assets. An increasing asset utilization means that Medy Tox is more efficient with each dollar of assets it utilizes for everyday operations.Medy Tox Ownership Allocation
The market capitalization of Medy Tox is W1 Trillion. Medy Tox holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with substantial debt, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company at some point.Medy Tox Profitability Analysis
The company reported the revenue of 184.87 B. Net Income was 94.15 B with profit before overhead, payroll, taxes, and interest of 105.47 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Medy Tox's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Medy Tox and how it compares across the competition.
About Medy Tox Valuation
The stock valuation mechanism determines Medy Tox's current worth on a weekly basis. Our valuation model uses a comparative analysis of Medy Tox. We calculate exposure to Medy Tox's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Medy Tox's related companies.Medy-Tox Inc., a biopharmaceutical company, develops, manufactures, markets, and sells botulinum toxin and hyaluronic acid dermal filler products primarily in South Korea. Medy-Tox Inc. was founded in 2000 and is headquartered in Cheongju, South Korea. MedyTox is traded on Korean Securities Dealers Automated Quotations in South Korea.
8 Steps to conduct Medy Tox's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Medy Tox's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Medy Tox's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Medy Tox's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Medy Tox's revenue streams: Identify Medy Tox's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Medy Tox's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Medy Tox's growth potential: Evaluate Medy Tox's management, business model, and growth potential.
- Determine Medy Tox's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Medy Tox's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Medy Stock analysis
When running Medy Tox's price analysis, check to measure Medy Tox's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medy Tox is operating at the current time. Most of Medy Tox's value examination focuses on studying past and present price action to predict the probability of Medy Tox's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medy Tox's price. Additionally, you may evaluate how the addition of Medy Tox to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |